RESUMO
OBJECTIVE: To explore the application prospect and clinical efficacy of transurethral plasmakinetic enucleation of the Giant prostatic hyperplasia. METHODS: The clinical data of 5 patients with Giant prostatic hyperplasia treated by transurethral plasmakinetic enucleation in our department from december 2021 to january 2023 were retrospectively analyzed. RESULTS: All 5 patients successfully completed the operation, aged 69ï¼80 years (73.2±4.32),PSA level was 8.07ï½42.90ng/ml (22.81±13.97), prostate volume was 321.05ï¼534.26g (388.34±84.26), enucleation time was 120ï¼240 min (174±61.48), Gland processing time 40ï¼120 minï¼63±32.71). There were 1 case of perforation of prostate capsule and severe hematuriaï¼3 cases of blood transfusion. 2 cases of transient urinary incontinence were improved after 2 weeks and 4 months postoperative respectively. International Prostate Symptom Score (IPSS),and quality of life score (QoL) and Maximum urine flow rate(Qmax) were significantly improved compared with preoperative parameters. CONCLUSION: It is safe and effective to treat GPH with plasma enucleation through urethra with skilled plasma enucleation technique.